| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 201 | Methods and use of lactic acid bacteria that acid resistance is increased | JP2009514240 | 2007-05-30 | JP2009539372A | 2009-11-19 | コノリー、イーモン |
| 本発明は、より良好な耐酸性の能力を有するように改変された乳酸菌の特定のプラスミドキュアリング菌株、かかる菌株の改変法、及びかかる菌株を含有する製品を提供する。 | ||||||
| 202 | How to use the 3-hpa producing Lactobacillus strain in combination with medium chain triglyceride oil to improve the immune function in a mammal | JP2008509976 | 2006-05-02 | JP2008540406A | 2008-11-20 | − ジン カン、ホ; コノリー、エイモン |
| 選択された３−ＨＰＡ産生乳酸菌と中鎖トリグリセリド（ＭＣＴ）油を用いる哺乳動物の免疫機能を向上させる方法。 | ||||||
| 203 | A method of increasing the animal feed conversion efficiency of | JP51699394 | 1993-11-16 | JPH08505775A | 1996-06-25 | マーク イー． クツク，; マイケル ダブリユー パリザ， |
| (57)【要約】 安全かつ有効な量の共役リノール酸を動物に投与することを含んでなる動物の重量増加と飼料の効率とを高める方法。 | ||||||
| 204 | JPH06505478A - | JP50585792 | 1992-01-28 | JPH06505478A | 1994-06-23 | |
| A method of establishing direct feed microorganisms such as Lactobacillus reuteri in the gastrointestinal tract of avian organisms in which eggs are inoculated with living cells of the microorganism. | ||||||
| 205 | Synbiotic mixture | US14639734 | 2015-03-05 | US10092606B2 | 2018-10-09 | Norbert Sprenger; Francois Morgan; Rafael Berrocal; Marcel Braun; Christine Cherbut; Peter Duncan |
| This invention relates to a preparation comprising a probiotic bacterial strain and a prebiotic mixture comprising 5-70 wt % of at least one N-acetylated oligosaccharide selected from the group consisting of Ga1NAcα1-3Ga1β1-4G1c, Ga1β1-6Ga1Nacα1-3Ga1β1-4G1c and combinations thereof, 20-95 wt % of at least one neutral oligosaccharide selected from the group consisting of Galβ1-6Gal, Galβ1-6Galβ1-4Glc, Galβ1-6Galβ1-6Glc, Galβ1-3Galβ1-3Glc, Galβ1-3Galβ1-4Glc, Galβ1-6Galβ1-6Galβ1-4Glc, Galβ1-6Galβ1-3Galβ1-4Glc, Galβ1-3Galβ1-6Galβ1-4Glc, Galβ1-3Galβ1-3Galβ1-4Glc and combinations thereof and 2-50 wt % of at least one sialylated oligosaccharide selected from the group consisting of NeuAcα2-3Galβ1-4Glc, NeuAcα2-6Ga1β1-4G1c and combinations thereof. The invention extends to food products comprising said preparation and to the use of the preparation in the prevention and treatment of infections. | ||||||
| 206 | LACTOBACILLUS STRAIN-CONTAINING FOOD COMPOSITE, ORAL CLEANING COMPOSITE AND MEDICAL COMPOSITE FOR INHIBITING ORAL PATHOGENS | US15867301 | 2018-01-10 | US20180206541A1 | 2018-07-26 | Pei-Shan HSIEH; Chung-Wei KUO; Yi-Chun TSAI; Hsieh-Hsun HO; Yi-Wei KUO |
| A food composite, an oral cleaning composite or a medical composite contain at least one lactobacillus strain able to inhibit oral pathogens. The lactobacillus strain is at least one isolated lactobacillus strain selected from a group including Lactobacillus acidophilus F-1 strain; Lactobacillus salivarius subsp. salicinius AP-32 strain; Lactobacillus reuteri GL-104 strain; Lactobacillus paracasei GL-156 strain; Lactobacillus helveticus RE-78 strain; Lactobacillus rhamnosus CT-53 strain; and Lactobacillus paracasei ET-66 strain. The abovementioned lactobacillus strains are able to inhibit oral pathogens and carried by a food composite, an oral cleaning composite or a medical composite. | ||||||
| 207 | Selection and Use of Lactic Acid Bacteria Preventing Bone Loss in Mammals | US15918207 | 2018-03-12 | US20180200313A1 | 2018-07-19 | Eamonn Connolly; Robert Allen Britton; Laura Rae McCabe |
| The present invention comprises a method for selecting lactic acid bacterial strains effective for preventing bone loss in humans and strains that have been selected according to the presented method. The selection method is based on the strain's capability of reestablishing an altered microbial community to normal and/or harboring at least one of four specific SNPs. | ||||||
| 208 | COMPOSITION & METHODS OF SCREENING | US15901637 | 2018-02-21 | US20180177817A1 | 2018-06-28 | Stephen Patrick O'HARA; Robert RASTALL |
| The present invention relates to a prebiotic composition comprising a microbially produced oligosaccharide, wherein the oligosaccharide is characterised by being selective for a pre-determined probiotic bacterial strain and also capable of being produced by the pre-determined probiotic bacteria by reverse enzyme action. The present invention also relates to methods of screening a composition suitable for use as a prebiotic and methods for screening of prebiotics for incorporation into synbiotic formulations. | ||||||
| 209 | Production and use of bacterial histamine | US15289666 | 2016-10-10 | US10004770B2 | 2018-06-26 | James Versalovic; Carissa Michelle Thomas; Eamonn Connolly |
| A method is provided of selecting specific probiotic lactic acid bacteria producing histamine and the use of such strains for beneficial effects for mammals. The method includes selecting a lactic acid bacterial strain for use in the local production of histamine in a mammal, and further comprises screening bacteria for the presence of an active histidine operon and selecting a strain which has an active histidine operon and is capable of producing histamine. Preferably said strain is selected for its ability to produce histamine at a level of greater than 250 pg/ml. The present invention further provides products comprising the strains obtainable by the selection methods of the invention for use in the local production of histamine in a mammal, in particular for use in the treatment or prophylaxis of inflammatory conditions. | ||||||
| 210 | Lactobacillus supplement for alleviating type 1 diabetes | US14656209 | 2015-03-12 | US09987313B2 | 2018-06-05 | Graciela Liliana Lorca |
| Isolated Lactobacillus strains are useful in preventing or delaying the development of Type 1 Diabetes (T1D). A probiotic composition comprising the Lactobacillus strains and use of the composition in T1D prevention are provided. | ||||||
| 211 | Selection and use of lactic acid bacteria preventing bone loss in mammals | US15331346 | 2016-10-21 | US09968643B2 | 2018-05-15 | Eamonn Connolly; Robert Allen Britton; Laura Rae McCabe |
| The present invention comprises a method for selecting lactic acid bacterial strains effective for preventing bone loss in humans and strains that have been selected according to the presented method. The selection method is based on the strain's capability of reestablishing an altered microbial community to normal and/or harboring at least one of four specific SNPs. | ||||||
| 212 | Composition and use of Lactobacillus reuteri GMNL-263 in decreasing blood lipid levels | US14618188 | 2015-02-10 | US09895400B2 | 2018-02-20 | Yi-Hsing Chen; Ya-Hui Chen; Tzu-Chi Lou; Ting-Yun Shen |
| A use of a Lactobacillus reuteri GMNL-263 in decreasing blood lipid levels is disclosed. Lactobacillus reuteri GMNL-263 (accession No.: CCTCC M 209263) specifically inhibits gene expression related to pro-inflammatory factor and lipid synthesis and promotes gene expression related to cholesterol metabolism. Lactobacillus reuteri GMNL-263 is utilized to produce a composition for decreasing blood lipid levels, thereby achieving the aim of hyperlipidemia treatment. | ||||||
| 213 | METHODS FOR DETERMINATION OF BIOACTIVITY, REMOVAL, OR INACTIVATION CEREAL AMYLASE TRYPSIN INHIBITORS IN CEREALS, FLOURS AND COMPLEX FOODS | US15308397 | 2015-04-30 | US20170049136A1 | 2017-02-23 | Detlef SCHUPPAN |
| The present invention features methods of extracting amylase trypsin inhibitors (ATIs) from processed and unprocessed foodstuff, determining bioactivity of ATIs, qualifying the amount of ATIs in a foodstuff, and reducing the content of ATIs in a foodstuff. | ||||||
| 214 | Lactobacillus supplement for alleviating type 1 diabetes | US13144028 | 2010-02-18 | US09474773B2 | 2016-10-25 | Josef Neu; Graciela Liliana Lorca; Eric W. Triplett; Mark A. Atkinson; Desmond A. Schatz |
| Isolated Lactobacillus strains are useful in preventing or delaying the development of Type 1 Diabetes (T1D). A probiotic composition comprising the Lactobacillus strains and use of the composition in T1D prevention are provided. | ||||||
| 215 | Method of Improving Immune Function in Mammals using Lactobacillus Strains with Certain Lipids | US15062558 | 2016-03-07 | US20160287702A1 | 2016-10-06 | Ho-Jin Kang; Eamonn Connolly |
| A method of improving immune-function in mammals using selected 3-HPA producing lactic acid bacteria with a medium chain triglyceride (MCT) oil. | ||||||
| 216 | Extruded non-replicating probiotic micro-organisms and their health benefits | US14541434 | 2014-11-14 | US09320767B2 | 2016-04-26 | Annick Mercenier; Antoine Wermeille; Audrey Demont; Guenolee Prioult |
| The present invention generally relates to the field of pro biotic micro-organisms, in particular to the field of non-replicating probiotic micro-organisms. Embodiments of the present invention relate to compositions comprising probiotic microorganisms that were rendered non-replicating by extrusion. Such compositions may be used to treat or prevent disorders that are related to a compromised immune system. | ||||||
| 217 | LACTOBACILLUS SUPPLEMENT FOR ALLEVIATING TYPE 1 DIABETES | US14656209 | 2015-03-12 | US20150182567A1 | 2015-07-02 | Graciela Liliana LORCA |
| Isolated Lactobacillus strains are useful in preventing or delaying the development of Type 1 Diabetes (T1D). A probiotic composition comprising the Lactobacillus strains and use of the composition in T1D prevention are provided. | ||||||
| 218 | Synbiotic mixture | US12281448 | 2007-03-07 | US09005682B2 | 2015-04-14 | Norbert Sprenger; Francois Morgan; Rafael Berrocal; Marcel Braun; Christine Cherbut; Peter Duncan |
| This invention relates to a preparation comprising a probiotic bacterial strain and a prebiotic mixture comprising 5-70 wt % of at least one N-acetylated oligosaccharide selected from the group comprising Ga1NAcα1,3Ga1β1,4G1c and Ga1β1,6Ga1NAcα1,3Ga1β1,4G1c, 20-95 wt % of at least one neutral oligosaccharide selected from the group comprising Ga1β1,6Ga1, Ga1β1,6Ga1β1,4G1c Ga1β1,6Ga1β1,6G1c, Ga1β1,3Ga1β1,3G1c, Ga1β1,3Ga1β1,4G1c, Ga1β 1,6Ga1β 1,6Ga1β 1,4GIc, Ga1β 1,6Ga1β 1,3Ga1β 1,4GIc Ga1β 1,3Ga1β 1,6Ga1β 1,4GIc and Ga1β1,3Ga1β1,3Ga1β1,4G1c and 2-50 wt % of at least one sialylated oligosaccharide selected from the group comprising NeuAcα2,3Ga1β1,4G1c and NeuAcα2,6Ga1β1,4G1c. The invention extends to food products comprising said preparation and to the use of the preparation in the prevention and treatment of infections. | ||||||
| 219 | INFANT CEREAL COMPRISING NON-REPLICATING PROBIOTIC MICROORGANISMS | US14550156 | 2014-11-21 | US20150079056A1 | 2015-03-19 | Annick Mercenier; Sophie Nutten; Guenolee Prioult |
| The present invention relates to the field of infant cereals. In particular, the present invention relates to the field of infant cereals that can be used to strengthen the immune system of the infant and/or that can be used to treat or prevent inflammatory disorders. For example these benefits can be provided by probiotic micro-organisms. An embodiment of the present invention relates to an infant cereal comprising non-replicating probiotic-micro-organisms, for example bioactive heat treated probiotic micro-organisms. | ||||||
| 220 | Extruded non-replicating probiotic micro-organisms and their health benefits | US13884543 | 2011-11-11 | US08961952B2 | 2015-02-24 | Annick Mercenier; Antoine Wermeille; Audrey Demont; Guenolee Prioult |
| The present invention generally relates to the field of probiotic micro-organisms, in particular to the field of non-replicating probiotic micro-organisms. Embodiments of the present invention relate to compositions comprising probiotic micro-organisms that were rendered non-replicating by extrusion. Such compositions may be used to treat or prevent disorders that are related to a compromised immune system. | ||||||
QQ群二维码
意见反馈
意见反馈